Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 10Neoplasms 4Neoplasm Metastasis 2Leiomyosarcoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Gemcitabine 677130-nm albumin-bound paclitaxel 197Fluorouracil 184Oxaliplatin 173Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 129Irinotecan 111Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 71Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 48Magnetic Resonance Spectroscopy 45folfirinox 42Docetaxel 41Cetuximab 40irinotecan sucrosofate 36Specimen Handling 36S 1 (combination) 36Biopsy 30Radiation 29Paclitaxel 29Ipilimumab 27Surgical Procedures, Operative 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × olaratumab × Clear all
NCT03086369 2022-06-28

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
184 enrolled 22 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡